Cue Biopharma
74 hedge funds and large institutions have $185M invested in Cue Biopharma in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
10% more capital invested
Capital invested by funds: $168M → $185M (+$17.5M)
3.29% more ownership
Funds ownership: 45.91% → 49.2% (+3.3%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $443K
Holders
74
Holding in Top 10
2
Calls
–
Puts
$443K
Top Buyers
| 1 | +$15.6M | |
| 2 | +$7.59M | |
| 3 | +$5.88M | |
| 4 |
Goldman Sachs
New York
|
+$2.22M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.77M |
Top Sellers
| 1 | -$1.14M | |
| 2 | -$826K | |
| 3 | -$627K | |
| 4 |
Morgan Stanley
New York
|
-$522K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$473K |